ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1097 • ACR Convergence 2022

    Intrinsic STAT1 Deficiency Underlies Proinflammatory Imprint of Naive CD4+ T Cells in Spondyloarthritis

    Bilade CHERQAOUI1, Frederic Cremazy1, Marc Lauraine1, Ghazal Shammas2, Roula Said-Nahal3, Hendrick Mambu Mambueni4, Felicie Costantino2, Marine Fourmont2, Simon Glatigny2, Luiza Maria Araujo2 and Maxime Breban2, 1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, 21INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, 3Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, 4Genomic Platform of Faculty of Health Simone Veil - UVSQ university, Montigny-le-Bretonneux, France

    Background/Purpose: Spondyloarthritis (SpA) development is associated with type 3 immune response activation. In HLA-B27/human β2-microglobulin transgenic rat model (B27-rat), this might at least be related…
  • Abstract Number: 1108 • ACR Convergence 2022

    Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis

    Danielle Stahlbaum1, Renea Jablonski1, Mary Strek2 and Pankti Reid1, 1University of Chicago Medical Center, Chicago, IL, 2University of Chicago, Chicago, IL

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
  • Abstract Number: 1107 • ACR Convergence 2022

    Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study

    Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China

    Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR,…
  • Abstract Number: 1106 • ACR Convergence 2022

    Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia Rheumatica on Glucocorticoid Therapy: A Randomized Clinical Trial

    Valerie Devauchelle1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, Christophe Richez4, Marie Truchetet5, Daniel Wendling6, ERIC TOUSSIROT7, aleth Perdriger8, jacques-eric gottenberg9, Renaud FELTEN10, Bruno Fautrel11, laurent chiche12, Pascal HILLIQUIN13, Catherine Le Henaff14, Benjamin Dervieux15, Guillaume Direz16, Isabelle Chary-Valckenaere17, Divi CORNEC18, Dewi Guellec19, Thierry MARHADOUR20, Emmanule Nowak19 and Alain Saraux21, 1Université de Bretagne Occidentale, Brest, France, 2CHRU de Tours, Tours, France, 3LE MANS general hospital, LE MANS, France, 4Université de Bordeaux, Bordeaux, France, 5Bordeaux University Hospital, Bordeaux, France, 6CHU, University Teaching Hospital, Besançon, France, 7CHU de Besançon, Besançon, France, 8Rennes University, Rennes, France, 9Strasbourg University Hospital, Strasbourg, France, 10Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 11Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, 12hopital europeen, Marseille, France, 13Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, 14Morlaix Hospital, Morlaix, France, 15Mulhouse Hospital, Mulhouse, France, 16Le Mans Hospital, Le Mans, France, 17Nancy University Hospital, Vandoeuvre, France, 18CHRU Brest, Brest, France, 19Brest University Hospital, Brest, France, 20CHU Cavale Blanche, Brest, France, 21CHU Brest, Brest, France

    Background/Purpose: Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica (PMR). Interleukin-6 antagonists deserve evaluation in active glucocorticoid-dependent PMR. Our objective was to compare…
  • Abstract Number: 1100 • ACR Convergence 2022

    Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States

    Jessica Williams1, Gaobin Bao1, Charmayne Dunlop-Thomas2, Cristina Drenkard2, Kim Schofield1 and S. Sam Lim2, 1Emory University School of Medicine, Atlanta, GA, 2Emory University, Atlanta, GA

    Background/Purpose: Black patients have higher incidence and severity of systemic lupus erythematosus (SLE) and worse outcomes as compared to White patients, yet Black patients are…
  • Abstract Number: 1112 • ACR Convergence 2022

    Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry

    Hafsah Nabi1, Oliver Hendricks2, Dorte Vendelbo Jensen3, Anne Gitte Loft4, Jens Pedersen5, Søren Just6, Kamilla Danebod7, Heidi Munk8, Salome Kristensen9, Natalia Manilo10, Ada Colic11, Asta Linauskas12, Pia Høger Thygesen13, Louise Christensen3, Maren Høgberget Kalisz3, Niels Lomborg14, Stavros Chrysidis15, Johnny Raun15, Marlene Andersen16, Frank Mehnert17, Niels Steen Krogh18, Merete L Hetland19 and Bente Glintborg20, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, 2Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, 3Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, 4Aarhus University, Horsens, Denmark, 5Svendborg Hospital, Odense University Hospital, Odense, Denmark, 6Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, 7Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, Odense, Denmark, 9Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 10Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, 11Department of Rheumatology, Zealand University Hospital, Køge, Denmark, 12North Denmark Regional Hospital, Hjørring, Denmark, 13Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, 14Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Denmark, Odense, Denmark, 15Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark, 16Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, 17Aarhus University Hospital, Aarhus, Denmark, 18ZiteLab ApS, Frederiksberg, Denmark, 19Rigshospitalet, Glostrup, Denmark, 20Rigshospitalet, Glostrup, Virum, Denmark

    Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…
  • Abstract Number: 1113 • ACR Convergence 2022

    Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study

    Thomas Dörner1, Antónia Szántó2, Jui-Cheng Tseng3, Martin Kaul4, Ilona Pylvaenaeinen5, Malika Hanser6, Nasri Abdallah6, Bruno Cenni6 and Richard Siegel6, 1Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 2Debreceni Egyetem Klinikai Centrum, Debrecen, Hungary, 3Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 4Independent Consultant, Neustadt, Germany, 5Early Development Analytics, Novartis Pharmaceutical AG, Basel, Switzerland, 6Novartis Institutes for BioMedical Research, Basel, Switzerland

    Background/Purpose: Sjögren's syndrome (SS) is a systemic autoimmune disease of unknown etiology characterized by B-cell hyperactivation, lymphoid infiltration, progressive destruction of exocrine glands, and various…
  • Abstract Number: 1103 • ACR Convergence 2022

    Needs Assessment of Musculoskeletal Ultrasound Training in North American Pediatric Rheumatology Fellowship Programs

    Megan Perron1, Sonja Ziniel2, Megan Curran3, Jessica Bloom4, Patricia Vega-Fernandez5, Heather Benham6, Karina Torralba7, Deirdre De Ranieri8 and Clara Lin9, 1Children's Hospital Colorado, Division of Rheumatology, Aurora, CO, 2University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, 3University of Colorado, Aurora, CO, 4University of Colorado, Denver, CO, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Scottish RIte Hospital, North Richland Hills, TX, 7Loma Linda University Faculty Medical Group, Redlands, CA, 8Lurie Children's Hospital, Chicago, IL, 9Children's Hospital Colorado, Aurora, CO

    Background/Purpose: Musculoskeletal Ultrasound (MSUS) has become widely used in rheumatology practice for diagnosis of arthritis and procedural guidance. A 2017 survey of adult rheumatology fellowship…
  • Abstract Number: 1111 • ACR Convergence 2022

    Sarcoidosis Rates in BCG-Vaccinated and Unvaccinated Young Adults: A Danish Register-Based Study

    Matthew Baker1, Emese Vágó2, Suzanne Tamang3, Erzsébet Horváth-Puhó2 and Henrik Sørensen2, 1Stanford University, Stanford, CA, 2Aarhus University Hospital, Aarhus, Denmark, 3Stanford Center for Population Health Sciences, Redwood City, CA

    Background/Purpose: The inciting factor or antigen exposure that initiates sarcoidosis remains unknown. However, an infectious trigger such as Mycobacterium spp. or Propionibacterium acnes infection may…
  • Abstract Number: 1124 • ACR Convergence 2022

    CD4+ Cytotoxic T Lymphocytes (CTL) Are Present in Sjögren’s Disease Minor Salivary Glands and Associate with Markers of Epithelial Cell Damage near Infiltrates

    Michelle Joachims1, Chuang Li1, Joshua Rusbuldt2, Ben Fowler1, Astrid Rasmussen1, Kiely Grundahl1, R. Hal Scofield3, Kathy Sivils4, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Janssen Research and Development, LLC, Spring House, PA

    Background/Purpose: CD4+ T cells dominate focal lymphocytic infiltrates in Sjögren's disease (SjD), but their differentiation states have remained unclear. Here, we used single cell (sc)RNAseq…
  • Abstract Number: 1118 • ACR Convergence 2022

    Monocyte Transcriptomic Analysis Uncovers Heterogeneous Gene Expression Profiles in Systemic Lupus Erythematous (SLE) with and Without Subclinical Atherosclerosis

    Laurel Woodridge1, Elvira Chocano Navarro2, George Robinson1, Paul Ashford1, Kirsty Waddington3, Anisur Rahman4, Christine Orengo5, Ines Pineda-Torra6 and Elizabeth Jury1, 1University College London, London, United Kingdom, 2VIHR, Barcelona, Spain, 3University College London (alumni), London, United Kingdom, 4Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 5ISMB / UCL, London, United Kingdom, 6Cabimer, Sevilla, Spain

    Background/Purpose: A leading cause of mortality in SLE is cardiovascular disease (CVD) through accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall.…
  • Abstract Number: 1120 • ACR Convergence 2022

    Transcriptome-Wide Association Study of Sjögren’s Disease Risk Alleles Identifies Novel Genes with Altered Expression in Minor Salivary Gland and Other Tissues

    Marcin Radziszewski1, Mandi Wiley1, Bhuwan Khatri1, Kandice Tessneer1, Astrid Rasmussen1, Professor Simon Bowman2, Lida Radfar3, Roald Omdal4, Marie Wahren-Herlenius5, Blake Warner6, Torsten Witte7, Roland Jonsson8, Maureen Rischmueller9, Patrick Gaffney1, Judith James1, Lars Ronnblom10, R. Hal Scofield3, Xavier Mariette11, Marta Alarcon-Riquelme12, Fai Ng13, Gunnel Nordmark10, Umesh Deshmukh1, A. Darise Farris1 and Christopher Lessard1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University Hospitals Birmingham, Birmingham, United Kingdom, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Stavanger University, Stavanger, Norway, 5Karolinska Institutet, Stockholm, Sweden, 6National Institutes of Health, Bethesda, MD, 7MH-Hannover, Hannover, Germany, 8University of Bergen, Bergen, Norway, 9RheumatologySA, Adelaide, Australia, 10Uppsala University, Uppsala, Sweden, 11Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 12Center for Genomics and Oncological Research (GENYO), Granada, Spain, 13Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

    Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease characterized by reduced function of exocrine glands, but also has systemic manifestations affecting multiple organs, including abnormal…
  • Abstract Number: 1116 • ACR Convergence 2022

    Peripheral Blood DNA Methylation-based Machine Learning Models for Prediction of Knee Osteoarthritis Progression: Biospecimens and Data from the Osteoarthritis Initiative and Johnston County Osteoarthritis Project

    Chris Dunn1, Cassandra Sturdy2, Cassandra Velasco3, Leoni Schlupp2, Emmaline Prinz2, Vladislav Izda4, Liubov Arbeeva5, Yvonne Golightly6, Amanda Nelson7 and Matlock Jeffries2, 1University of Oklahoma Health Sciences Center, Edmond, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Oklahoma Medical Research Foundation, New York, NY, 5University of North Carolina Chapel Hill, Chapel Hill, NC, 6University of Nebraska Medical Center, Omaha, NE, 7University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes, for which there exist no widely-available biomarkers. We…
  • Abstract Number: 1126 • ACR Convergence 2022

    Functional NOTCH4 Variants Increase Notch Signaling and Susceptibility for Systemic Sclerosis

    Urvashi Kaundal1, Emilee Stenson1, Mousumi Sahu1, Krishan Kumar Thakur1, Janet Wang1, Ami Shah2, Maureen Mayes3, Ayo Doumatey4, Amy Bentley4, Daniel Shriner4, Robyn Domsic5, Thomas Medsger6, Paula Ramos7, Richard Silver7, Virginia Steen8, John Varga9, Vivien Hsu10, Lesley Ann Saketkoo11, Elena Schiopu12, Dinesh Khanna13, Jessica Gordon14, Lindsey Criswell15, Heather Gladue16, Chris Derk17, Elana Bernstein18, S. Louis Bridges, Jr.14, Victoria Shanmugam19, Lorinda Chung20, Suzanne Kafaja21, Reem Jan22, Marcin Trojanowski23, Avram Goldberg24, Benjamin Korman25, Jim Mullikin4, Stefania Dell'Orso1, Adebowale Adeyemo4, Charles Rotimi4, Elaine Remmers4, Daniel Kastner4, Fredrick Wigley26, Francesco Boin27 and Pravitt Gourh28, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2Johns Hopkins Rheumatology, Baltimore, MD, 3Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 4National Human Genome Research Institute, Bethesda, MD, 5University of Pittsburgh, Pittsburgh, PA, 6University of Pittsburgh School of Medicine, Pittsburgh, PA, 7Medical University of South Carolina, Charleston, SC, 8Georgetown University School of Medicine, Washington, DC, 9University of Michigan, Ann Arbor, MI, 10Rutgers-RWJ Medical School, South Plainfield, NJ, 11University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 12Michigan Medicine, Ann Arbor, MI, 13Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 14Hospital for Special Surgery, New York, NY, 15National Human Genome Research Institute, NIH, Bethesda, MD, 16Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 17University of Pennsylvania, Philadelphia, PA, 18Columbia University, New York, NY, 19George Washington University, Great Falls, VA, 20Stanford University, Stanford, CA, 21UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, 22University of Chicago, Chicago, IL, 23Boston University School of Medicine, Boston, MA, 24NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, 25University of Rochester, Rochester, NY, 26Johns Hopkins University, Baltimore, MD, 27Cedars-Sinai Medical Center, Los Angeles, CA, 28National Institutes of Health, Bethesda, MD

    Background/Purpose: Genome wide association studies (GWAS) in systemic sclerosis (SSc) have identified several genetic loci, but the search for the causal variant and gene continues.…
  • Abstract Number: 1070 • ACR Convergence 2022

    Discordance of Patient, Physician and Nurse Practitioner Assessment of Disease Burden in Systemic Sclerosis

    Maylen Nordgård Carstens1, Håvard Fretheim1, Imon Barua1, Henriette Didriksen2, Torhild Garen1, Øyvind Midtvedt1, Øyvind Molberg3 and Anna-Maria Hoffmann-Vold1, 1Oslo University Hospital, Oslo, Norway, 2Oslo University Hospital, Moss, Norway, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Assessment of disease burden is crucial in the management of systemic sclerosis (SSc). The patient global assessment (PatGA) is a patient self-reported measure widely…
  • « Previous Page
  • 1
  • …
  • 555
  • 556
  • 557
  • 558
  • 559
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology